TLDR:
- Symbiotic Capital, co-founded by Arie Belldegrun, has $600 million to lend to established life science companies.
- The lender is part of Belldegrun’s investment empire, Bellco Capital, and aims to fill a void in lending to the life science industry.
A new lender, Symbiotic Capital, has emerged in Los Angeles with a focus on established life science companies. Co-founded by Arie Belldegrun and Russell Goldsmith, the non-bank lender has raised over $600 million in capital to provide loans to companies in the pharmaceutical, medical device, and health tech sectors. Symbiotic has already made several loans and credit facilities totaling hundreds of millions of dollars since last fall, with a specific focus on life science companies in need of major capital infusions.
What sets Symbiotic apart is its team of industry experts, including former pharmaceutical company executives, health clinic leaders, venture capital investors, and bioscience scholars. This unique panel of experts helps the lender make informed credit decisions tailored to the needs of established healthcare enterprises. Arie Belldegrun, the mastermind behind Bellco Capital, sees Symbiotic as a science-first credit platform designed to support the groundbreaking work of life science companies in the current financial climate.
With a background in creating bioscience ecosystems, Belldegrun has used Bellco Capital to build a biotech funding and real estate empire over the past two decades. Symbiotic Capital is the latest addition to his investment portfolio, filling a gap in the market for lenders devoted exclusively to life science companies. By offering term loans ranging from $20 million to $50 million, with the potential to participate in larger deals with co-investors, Symbiotic aims to provide much-needed financial support to companies in the industry.
Overall, Symbiotic Capital’s launch represents a significant development in the Los Angeles business landscape, offering a specialized lending solution to an industry facing economic challenges and tight capital markets. With Belldegrun and Goldsmith at the helm, Symbiotic is poised to make a meaningful impact on the growth and innovation of established life science companies in the region.
